Does metoprolol cause gynaecomastia? This is a question raised by patients and clinicians alike, given that metoprolol — a cardioselective beta-1 blocker widely prescribed across the UK for hypertension, angina, heart failure, and arrhythmias — lists gynaecomastia as a potential adverse effect in some UK Summary of Product Characteristics documents. Whilst the association is recognised, it is classified as rare or of unknown frequency depending on the specific preparation, and a definitive causal mechanism has not been established. This article explores the evidence, how to assess risk, when to seek medical advice, and what options are available if you are affected.

Can Metoprolol Cause Gynaecomastia?

Metoprolol can cause gynaecomastia, listed as rare or frequency not known in UK SmPC documents; the association is based mainly on post-marketing reports and a definitive mechanism has not been established.

Metoprolol is a cardioselective beta-1 adrenoceptor blocker widely prescribed in the UK for conditions including hypertension, angina, heart failure, and certain arrhythmias. It works by selectively blocking beta-1 receptors in the heart, reducing heart rate and cardiac output, and thereby lowering blood pressure and myocardial oxygen demand.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — has been reported as an adverse effect in association with metoprolol. The frequency listed in UK Summary of Product Characteristics (SmPC) documents for metoprolol preparations varies by product; some list gynaecomastia as 'rare' (fewer than 1 in 1,000 patients), whilst others classify it as 'frequency not known' based on post-marketing surveillance data. Patients and clinicians should consult the specific SmPC for the metoprolol product prescribed, available via the Electronic Medicines Compendium (EMC).

It is important to distinguish true gynaecomastia — which involves proliferation of glandular breast tissue and typically presents as a firm, disc-like mass beneath the nipple — from pseudogynaecomastia, which is caused by fatty tissue deposition in the breast area and is associated with obesity rather than hormonal change. This distinction is relevant both clinically and when assessing whether a medicine such as metoprolol may be contributing.

The association between metoprolol and gynaecomastia is based largely on spontaneous post-marketing reports rather than robust clinical trial data, and a definitive causal mechanism has not been established. Patients who notice breast swelling, tenderness, or enlargement whilst taking metoprolol should not stop the medication abruptly — doing so can be dangerous, particularly in those with heart conditions — but should instead seek prompt medical advice from their GP or pharmacist.

How Beta-Blockers May Affect Hormone Balance

The mechanism by which metoprolol may cause gynaecomastia is unclear; proposed hypotheses include modest prolactin elevation and altered sex hormone metabolism, but none are reliably demonstrated for metoprolol specifically.

To understand why metoprolol might contribute to gynaecomastia, it is helpful to consider how hormonal balance influences breast tissue in males. Gynaecomastia typically arises when the ratio of oestrogen to androgen (particularly testosterone) activity is disrupted — either through increased oestrogen, reduced testosterone, or increased sensitivity of breast tissue to oestrogen.

The precise mechanism by which metoprolol — or beta-blockers as a class — might contribute to gynaecomastia is not established. Several hypotheses have been proposed in the medical literature, but these remain speculative and are not well supported by high-quality human data specific to metoprolol:

• Prolactin elevation: It has been suggested that some beta-blockers may modestly influence prolactin levels via dopaminergic pathways, though evidence for this with metoprolol specifically is limited.

• Reduced testosterone synthesis: There is very limited and inconclusive evidence that beta-adrenergic blockade could affect testicular Leydig cell function; this has not been demonstrated reliably for metoprolol.

• Altered sex hormone metabolism: Indirect effects on hepatic metabolism of sex hormones have been proposed but remain unproven.

Given the uncertainty, it is most accurate to state that the mechanism — if any — by which metoprolol might cause gynaecomastia is unclear, and the evidence is largely derived from case reports and post-marketing surveillance. Metoprolol's cardioselectivity means its actions are more targeted than those of non-selective beta-blockers, which may be relevant to its overall hormonal impact. Individual susceptibility — influenced by age, body composition, and concurrent medications — can vary considerably, and in many cases an alternative explanation for gynaecomastia will be identified on clinical review.

How Common Is Gynaecomastia With Metoprolol?

Gynaecomastia with metoprolol is classified as rare (fewer than 1 in 1,000) or frequency not known depending on the preparation; the large majority of patients taking metoprolol will not experience this side effect.

The frequency of gynaecomastia associated with metoprolol varies across UK-licensed product SmPCs. Some preparations list it as a rare adverse reaction (fewer than 1 in 1,000 treated individuals), whilst others record it as frequency not known — reflecting that the estimate cannot be reliably determined from available post-marketing data. Clinicians and patients should refer to the relevant product SmPC on the EMC for the specific preparation being used.

For context, drug-induced gynaecomastia is thought to account for a meaningful proportion of gynaecomastia cases seen in clinical practice, though precise estimates vary in the literature and should be interpreted cautiously. Within the range of medicines implicated, beta-blockers as a class are generally considered lower-risk compared to drugs such as spironolactone, anti-androgens, or anabolic steroids.

Whether cardioselective agents such as metoprolol carry a meaningfully different risk from non-selective beta-blockers (such as propranolol) with respect to gynaecomastia has not been robustly established in comparative studies; any such distinction should be regarded as uncertain. Age is an important contextual factor — older men, particularly those over 50, are more susceptible to gynaecomastia due to naturally declining testosterone levels, meaning any additional hormonal perturbation from medication may have a more pronounced effect. Patients should be reassured that the large majority of people taking metoprolol will not experience this side effect.

Other Medicines and Factors That Can Cause Gynaecomastia

Many medicines and physiological conditions cause gynaecomastia; spironolactone, digoxin, anti-androgens, and antipsychotics associated with hyperprolactinaemia carry stronger evidence than metoprolol.

When evaluating a patient presenting with gynaecomastia whilst taking metoprolol, it is essential to consider the full clinical picture, as many other factors — both pharmacological and physiological — are frequently responsible.

Medicines with well-established or strong associations with gynaecomastia include:

• Spironolactone (an aldosterone antagonist frequently co-prescribed in heart failure) — one of the most common drug causes

• Digoxin — a cardiac glycoside with oestrogenic properties

• Cimetidine (an H2 antagonist)

• Anti-androgens and hormonal therapies (e.g., finasteride, bicalutamide, cyproterone acetate)

• Anabolic steroids and testosterone replacement therapy

• Antipsychotics associated with hyperprolactinaemia (e.g., risperidone, amisulpride, haloperidol) — these have stronger evidence than antidepressants, for which the association is less well established

• Opioids (with longer-term use)

Medicines with possible but less certain associations include:

• Proton pump inhibitors (e.g., omeprazole) — reported in some cases but evidence is limited and inconsistent

• Cannabis — reported in some case series but evidence is inconsistent

Physiological causes are also important to exclude. These include pubertal gynaecomastia (common and usually self-limiting in adolescents), age-related hormonal changes in older men, obesity (which increases peripheral conversion of androgens to oestrogens), liver disease, renal failure, hyperthyroidism, and testicular or adrenal tumours.

A GP will typically conduct a thorough medication review alongside relevant investigations before attributing gynaecomastia to any single drug. In line with NICE CKS guidance on gynaecomastia, relevant blood tests may include testosterone, oestradiol, LH, FSH, prolactin, beta-hCG (to exclude germ cell tumours), thyroid function, and liver and renal function. Testicular examination is an important part of the clinical assessment, and testicular ultrasound should be considered where a testicular abnormality is suspected. NICE guidance supports a structured, stepwise approach to investigation in primary care.

When to Speak to Your GP or Pharmacist

Seek prompt GP advice for any breast changes whilst taking metoprolol; men aged 50 and over with an unexplained unilateral breast lump should be referred urgently via the 2-week-wait pathway per NICE NG12.

If you are taking metoprolol and notice any changes in your breast tissue — such as swelling, tenderness, a firm lump beneath the nipple, or nipple discharge — it is important to seek medical advice promptly. Whilst gynaecomastia is usually benign, breast changes in males should always be assessed to rule out other causes, including the rare possibility of male breast cancer.

You should contact your GP if you experience:

• Unilateral (one-sided) breast swelling or a hard, irregular lump

• Nipple discharge, particularly if bloodstained

• Rapid or progressive breast enlargement

• Associated symptoms such as unexplained weight loss, fatigue, or testicular changes

• Breast changes that are causing significant pain or psychological distress

Urgent referral: In line with NICE guidance on suspected cancer (NG12), men aged 50 and over with an unexplained unilateral breast lump should be referred urgently via the 2-week-wait pathway for assessment. Any man with a testicular mass should also be assessed urgently. If you are concerned about any of these features, contact your GP without delay.

Have questions about your medication? Our pharmacists are here to help →

Your pharmacist can also be a valuable first point of contact. They can review your full medication list to identify any other potential contributing drugs and advise on whether a GP appointment is warranted. Do not stop taking metoprolol without medical guidance — abrupt withdrawal can precipitate rebound hypertension, angina, or cardiac arrhythmias, particularly in patients with established cardiovascular disease.

The MHRA encourages patients and healthcare professionals to report suspected adverse drug reactions, including gynaecomastia, via the Yellow Card scheme (available at yellowcard.mhra.gov.uk). This reporting helps improve the safety monitoring of all medicines used in the UK.

Alternatives and Next Steps if You Are Affected

If metoprolol is implicated, options include dose reduction, switching to bisoprolol, changing drug class per NICE guidelines, or watchful waiting; all changes should be made under medical supervision.

If your GP concludes that metoprolol is likely contributing to gynaecomastia, there are several management options to consider, depending on your underlying condition and overall health profile. Any changes to cardiac or antihypertensive medication should always be made under medical supervision, and specialist input (for example from a cardiologist) is important before altering treatment for heart failure or arrhythmia.

Possible next steps include:

• Medication review and dose adjustment: In some cases, reducing the dose of metoprolol may alleviate the side effect whilst maintaining therapeutic benefit, though this should be balanced against clinical need.

• Switching to an alternative beta-blocker: Your GP or cardiologist may consider switching to another cardioselective agent such as bisoprolol, which has a similar pharmacological profile. It should be noted that whether switching within the beta-blocker class reliably resolves gynaecomastia is uncertain, and this decision should involve shared decision-making with your clinical team.

• Switching to a different drug class: Depending on the indication, alternative antihypertensive or cardiac agents — such as ACE inhibitors, angiotensin receptor blockers (ARBs), or calcium channel blockers — may be appropriate substitutes, in line with NICE guidelines for hypertension (NG136) or chronic heart failure (NG206).

• Watchful waiting: If the gynaecomastia is mild and not causing significant distress, and the benefit of metoprolol outweighs the risk, a period of observation may be recommended. Drug-associated gynaecomastia may improve once the causative agent is discontinued or changed, though resolution is not guaranteed.

• Referral: Persistent or severe gynaecomastia may warrant referral to an endocrinologist or breast surgeon for further assessment and, in some cases, surgical management.

Open communication with your healthcare team is key to finding the safest and most effective solution for your individual circumstances.

Frequently Asked Questions